Alnylam Pharmaceuticalsvs.Incyte
ALNY vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.2× larger than Incyte by market cap; Incyte trades at the lower P/E (15.1 vs 37.6); year to date, Incyte leads (+29.6% vs −40.6%).
Side by side
| ALNY | INCY | |
|---|---|---|
| Market cap | $30.4B | $24.4B |
| Price | $240.08 | $129.72 |
| Today | +1.7% | +1.4% |
| Return YTD | −40.6% | +29.6% |
| Return 1Y | −48.1% | +50.5% |
| P/E | 37.6 | 15.1 |
| P/S | 6.3 | 4.2 |
| P/B | 22.4 | 3.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More ALNY & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and INCY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →